iMediSync successfully debuted its novel headset for mental healthcare, iSyncWave at CES 2021.
iSyncWave™ and its AI brain mapping attracted global pharmaceuticals for their trials and global media looking for a solution to cope with the “corona blues”.
The keywords of CES 2021 All-Digital, announced by CTA(Consumer Technology Association) was AI, 5G, Digital Health, and Smart City. Especially in health and wellness fields, more attention paid to cloud platform to store personal health data for virtual and home care.
iMediSync perfectly targeted this new trend and has received global recognition. The company provides cloud-based AI brain mapping solutions with EEG data for early detection of neurological disorders. iSyncWave™ and iSyncMe® showcased in CES 2021 completes a virtual care platform of iMediSync. An easy and time-saving EEG brain mapping and personalized LED therapy device can be used not only in clinics but also at homes by individuals.
iMediSync claims they will tack the current mental pandemic and Corona Blue with its novel approach to biomarker development and personalized photobiomodulation therapy. iSyncWave™ is AI brain Mapping and personalized NIR-LED photobiomodulation therapy that will enhance neural activity; optimizing a person’s brain. This will accessible not only at your doctor’s clinic, but at the comfort of your own home. The healthcare professionals can provide their patients with a constant care when they are even at home.
iMediSync is a leading company in an EEG brain mapping market that has currently tackled Alzheimer’s. The company’s core product is iSyncBrain® MCI classifier. It provides QEEG-AI algorithm for early detection of mild cognitive impariement or preclinical Alzheimer’s dementia.
CES ended last week, but iMediSync will continue to expand its network for the next 30 days. The CES digital venue will remain opened until Feb15 where you can leave messages for iMediSync through the system. https://digital.ces.tech/exhibitor/5a85273d-ece3-4d37-ad38-7ab3b4c66f50?source=exhibitors
Or you can visit iMediSync’s Virtual booth at http://virtual.imedisync.com .
About CES
CES® is the most influential tech event in the world —proving the ground for breakthrough technologies and global innovators. This is where the world's biggest brands do business and meet new partners, and the sharpest innovators hit the stage. Owned and produced by the Consumer Technology Association (CTA)®, CES features every aspect of the tech sector.
About iMediSync
iMediSync (www.imedisync.com) has developed an AI-driven early detection and therapeutic platform for optimal brain health. iMediSync launched its first solution to detect Mild Cognitive Impairment (early stage of Alzheimer’s Disease) based on its proprietary EEG database in Korea last August 2020 (iSyncBrain MCI Classifier – KFDA Cleared). They conducted the clinical trial with multicenter hospitals with the result of 90%+ accuracy for its solution. The vision of iMediSync, just like iSyncBrain MCI Classifier, is to develop early detecting biomarkers for challenging neurological disorders and diseases, such as COMA, Parkinson’s, ADHD, Depression and etc.
Contact
Joshua Choi, General Manager of Sales & Marketing, iMediSync, Inc.
actsjung@imedisync.com
Jane Han, Manager of Sales & Marketing, iMediSync, Inc.
janehan@imedisync.com
